JPH11509212A - 亜鉛及び必要に応じてリシン又はカルシウムイオンでプレ処理された成長ホルモンを含む安定化医薬製剤 - Google Patents

亜鉛及び必要に応じてリシン又はカルシウムイオンでプレ処理された成長ホルモンを含む安定化医薬製剤

Info

Publication number: JPH11509212A
Authority: JP; Japan
Prior art keywords: growth hormone; zinc; lysine; calcium ions; formulation
Prior art date: 1995-07-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP9506179A

Other languages

English (en)

Japanese (ja)

Inventor

クリステンセン，トーキルド

バルシュミット，ペール

ホルムガードソーレンセン，ハンス

ビルステッドオルセン，オレ

ティム，ラース

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-14

Filing date

1996-06-28

Publication date

1999-08-17

1996-06-28 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

1999-08-17 Publication of JPH11509212A publication Critical patent/JPH11509212A/ja

Status Pending legal-status Critical Current

Links

102000018997 Growth Hormone Human genes 0.000 title claims abstract description 72
108010051696 Growth Hormone Proteins 0.000 title claims abstract description 72
239000000122 growth hormone Substances 0.000 title claims abstract description 68
239000011701 zinc Substances 0.000 title claims abstract description 31
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 25
229910052725 zinc Inorganic materials 0.000 title claims abstract description 25
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 24
239000004472 Lysine Substances 0.000 title claims abstract description 24
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 title claims abstract description 19
229910001424 calcium ion Inorganic materials 0.000 title claims abstract description 19
239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
239000000203 mixture Substances 0.000 claims abstract description 53
238000009472 formulation Methods 0.000 claims abstract description 48
238000002360 preparation method Methods 0.000 claims description 17
238000000034 method Methods 0.000 claims description 15
239000000243 solution Substances 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 12
239000007864 aqueous solution Substances 0.000 claims description 7
150000005846 sugar alcohols Chemical class 0.000 claims description 7
230000012010 growth Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 5
239000005556 hormone Substances 0.000 claims description 4
229940088597 hormone Drugs 0.000 claims description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
206010056438 Growth hormone deficiency Diseases 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000011592 zinc chloride Substances 0.000 claims description 2
235000005074 zinc chloride Nutrition 0.000 claims description 2
239000008367 deionised water Substances 0.000 claims 1
229910021641 deionized water Inorganic materials 0.000 claims 1
230000006240 deamidation Effects 0.000 abstract description 12
238000003860 storage Methods 0.000 abstract description 5
230000003647 oxidation Effects 0.000 abstract description 4
238000007254 oxidation reaction Methods 0.000 abstract description 4
238000003776 cleavage reaction Methods 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1
239000000854 Human Growth Hormone Substances 0.000 description 40
108010000521 Human Growth Hormone Proteins 0.000 description 40
102000002265 Human Growth Hormone Human genes 0.000 description 40
235000018977 lysine Nutrition 0.000 description 16
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
235000014304 histidine Nutrition 0.000 description 14
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 14
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
235000019445 benzyl alcohol Nutrition 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
239000004475 Arginine Substances 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
239000004471 Glycine Substances 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
235000009697 arginine Nutrition 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
238000002203 pretreatment Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000000539 dimer Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000012931 lyophilized formulation Substances 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
150000003248 quinolines Chemical class 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
150000003462 sulfoxides Chemical class 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
206010013883 Dwarfism Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108010013127 Met-human growth hormone Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
108010020346 Polyglutamic Acid Proteins 0.000 description 2
208000020221 Short stature Diseases 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229960001231 choline Drugs 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000011033 desalting Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
229920002643 polyglutamic acid Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
FSJVVVCZSRCTBM-RXSVEWSESA-N (2S)-2-[(2R)-3,4-dihydroxy-5-oxo-2H-furan-2-yl]-2-hydroxyethanolate 2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.O[C@@H](C[O-])[C@H]1OC(=O)C(O)=C1O FSJVVVCZSRCTBM-RXSVEWSESA-N 0.000 description 1
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
WEZNMMBMSZOXAZ-UHFFFAOYSA-N 2-boronooxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOB(O)O WEZNMMBMSZOXAZ-UHFFFAOYSA-N 0.000 description 1
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
RPERJPYDELTDMR-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RPERJPYDELTDMR-UHFFFAOYSA-K 0.000 description 1
KZSXRDLXTFEHJM-UHFFFAOYSA-N 5-(trifluoromethyl)benzene-1,3-diamine Chemical compound NC1=CC(N)=CC(C(F)(F)F)=C1 KZSXRDLXTFEHJM-UHFFFAOYSA-N 0.000 description 1
235000019737 Animal fat Nutrition 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
235000019743 Choline chloride Nutrition 0.000 description 1
239000004381 Choline salt Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
206010017788 Gastric haemorrhage Diseases 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920000805 Polyaspartic acid Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
208000026928 Turner syndrome Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
210000004198 anterior pituitary gland Anatomy 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004874 choline bitartrate Drugs 0.000 description 1
QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
229960003178 choline chloride Drugs 0.000 description 1
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical group [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
235000019417 choline salt Nutrition 0.000 description 1
238000010367 cloning Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000002242 deionisation method Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
108700003601 dimethylglycine Proteins 0.000 description 1
VCSZKSHWUBFOOE-UHFFFAOYSA-N dioxidanium;sulfate Chemical compound O.O.OS(O)(=O)=O VCSZKSHWUBFOOE-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical compound OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940078490 n,n-dimethylglycine Drugs 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229950004354 phosphorylcholine Drugs 0.000 description 1
PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
229920002714 polyornithine Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
230000002294 pubertal effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

JP9506179A 1995-07-14 1996-06-28 亜鉛及び必要に応じてリシン又はカルシウムイオンでプレ処理された成長ホルモンを含む安定化医薬製剤 Pending JPH11509212A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US119395P	1995-07-14	1995-07-14
US60/001,193		1995-07-14
PCT/DK1996/000293 WO1997003692A1 (en)	1995-07-14	1996-06-28	A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions

Publications (1)

Publication Number	Publication Date
JPH11509212A true JPH11509212A (ja)	1999-08-17

Family

ID=21694837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9506179A Pending JPH11509212A (ja)	1995-07-14	1996-06-28	亜鉛及び必要に応じてリシン又はカルシウムイオンでプレ処理された成長ホルモンを含む安定化医薬製剤

Country Status (14)

Country	Link
EP (1)	EP0839049A1 (cs)
JP (1)	JPH11509212A (cs)
KR (1)	KR19990028981A (cs)
CN (1)	CN1190897A (cs)
AU (1)	AU715997B2 (cs)
BR (1)	BR9609741A (cs)
CA (1)	CA2226523A1 (cs)
CZ (1)	CZ9498A3 (cs)
HU (1)	HUP9802287A3 (cs)
IL (1)	IL122583A0 (cs)
NO (1)	NO980155L (cs)
PL (1)	PL324379A1 (cs)
WO (1)	WO1997003692A1 (cs)
ZA (1)	ZA965368B (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998027980A2 (en) *	1996-12-20	1998-07-02	Takeda Chemical Industries, Ltd.	Method of producing a sustained-release preparation
US6191107B1 (en)	1997-09-26	2001-02-20	Takeda Chemical Industries, Ltd.	Complex of human growth hormone and zinc
NZ525914A (en)	1998-03-10	2004-03-26	Genentech Inc	Novel polypeptides and nucleic acids encoding the same
AU740405B2 (en)	1998-05-15	2001-11-01	Genentech Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en)	1998-05-15	2017-01-04	Genentech, Inc.	Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en)	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
DE60043367D1 (de)	1999-06-15	2009-12-31	Genentech Inc	Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CA2491433A1 (en)	1999-12-01	2001-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897945T3 (da)	1999-12-23	2012-05-07	Genentech Inc	IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
CA2397207C (en)	2000-01-13	2013-12-03	Genentech, Inc.	Novel stra6 polypeptides
AU2001238540A1 (en)	2000-02-24	2001-09-03	Monsanto Technology Llc	Non-aqueous injectable formulations for extended release of somatotropin
US6740520B2 (en)	2000-03-21	2004-05-25	Genentech, Inc.	Cytokine receptor and nucleic acids encoding the same
DE60120372T2 (de)	2000-03-24	2007-07-05	Genentech Inc., San Francisco	Verwendung von insulin zur behandlung von knorpelkrankheiten
AU6531101A (en)	2000-06-02	2001-12-17	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271491A1 (en)	2000-06-26	2002-01-08	Monsanto Technology Llc	Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en)	2000-06-30	2003-12-16	Monsanto Technology Llc	Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
CA2418960A1 (en)	2000-08-07	2002-02-14	Inhale Therapeutic Systems, Inc.	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
ATE412009T1 (de)	2000-08-24	2008-11-15	Genentech Inc	Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en)	2000-09-01	2008-09-17	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en)	2000-10-27	2004-01-06	Genentech, Inc.	Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
SI1485477T1 (sl)	2002-02-25	2009-10-31	Genentech Inc	Novi citokinski receptor GLM-R tipa 1
MXPA05010555A (es)	2003-04-04	2006-03-09	Genentech Inc	Formulaciones de proteina y anticuerpo de alta concentracion.
WO2005001486A1 (en)	2003-06-06	2005-01-06	Genentech, Inc.	Modulating the interaction between hgf beta chain and c-met
EP2784084B2 (en)	2003-07-08	2023-10-04	Novartis Pharma AG	Antagonist antibodies to IL-17A/F heterologous polypeptides
CA2548282A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en)	2004-02-12	2009-01-27	Montana State University	Snow mountain virus genome sequence, virus-like particles and methods of use
AU2005229434B2 (en)	2004-03-30	2010-09-30	Nsgene A/S	Therapeutic use of a growth factor, NsG33
MX2007004676A (es)	2004-10-27	2007-11-14	Univ Denver	Analogos de la hormona adrenocorticotropica y metodos relacionados.
WO2006132788A2 (en)	2005-06-06	2006-12-14	Genentech, Inc.	Transgenic models for different genes and their use for gene characterization
WO2008018854A2 (en)	2005-06-06	2008-02-14	The Rockefeller University	Bactiophage lysins for bacillus anthracis
HUE029021T2 (en)	2005-06-21	2017-02-28	Xoma (Us) Llc	IL-1beta-binding antibodies and fragments thereof
US7582291B2 (en)	2005-06-30	2009-09-01	The Rockefeller University	Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1922410A2 (en)	2005-08-15	2008-05-21	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
CA2620903A1 (en)	2005-08-24	2007-03-01	The Rockefeller University	Ply-gbs mutant lysins
EP1962584A2 (en)	2005-11-21	2008-09-03	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
BRPI0621124A2 (pt)	2005-12-22	2011-11-29	Genentech Inc	métodos para recuperação de uma proteìna de ligação à heparina
TWI341844B (en)	2006-02-02	2011-05-11	Trimeris Inc	Hiv fusion inhibitor peptides with improved biological properties
EP2050335A1 (en)	2006-02-17	2009-04-22	Genentech, Inc.	Gene disruptions, compositions and methods relating thereto
RU2008141912A (ru)	2006-03-23	2010-04-27	Новартис АГ (CH)	Противоопухолевые лекарства на основе антител к клеточным антигенам
EP2002259B1 (en)	2006-04-10	2012-05-16	Genentech, Inc.	Disheveled PDZ modulators
CA2649387A1 (en)	2006-04-19	2008-03-27	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
BRPI0621841B8 (pt) *	2006-07-06	2021-05-25	Daewoong Co Ltd	formulação líquida
EP3124045A3 (en)	2006-12-20	2017-05-03	Xoma (Us) Llc	Treatment of il-1 beta related diseases
CN101361968B (zh)	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
SI2391650T1 (sl)	2007-12-20	2015-03-31	Xoma (Us) Llc	Postopki za zdravljenje protina
PE20110543A1 (es)	2008-08-15	2011-08-04	Ironwood Pharmaceuticals Inc	Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
EP2331077A2 (en) *	2008-09-04	2011-06-15	Ironwood Pharmaceuticals, Inc.	Stable forlulation comprising therapeutic polypeptides for oral administration
CA2770077A1 (en) *	2009-08-06	2011-02-10	Ironwood Pharmaceuticals, Inc.	Formulations comprising linaclotide
KR101952453B1 (ko)	2009-10-15	2019-02-26	제넨테크, 인크.	수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
WO2011056561A1 (en)	2009-10-27	2011-05-12	Beth Israel Deaconess Medical Center	Methods and compositions for the generation and use of conformation-specific antibodies
MX349301B (es)	2009-12-21	2017-07-21	Ambrx Inc	Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt)	2009-12-21	2017-01-31	Ambrx Inc	peptídeos de somatotropina suínos modificados e seus usos
BR112012017535A2 (pt)	2010-01-15	2019-09-24	Of Medicine And Dentistry Of New Jersey University	uso de compostos de vanádio para cicatrização de osso
UA108636C2 (xx)	2010-02-17	2015-05-25		Пептид
EP2550018B1 (en)	2010-03-22	2019-02-27	F.Hoffmann-La Roche Ag	Compositions and methods useful for stabilizing protein-containing formulations
BR112012027828A2 (pt)	2010-05-03	2016-08-09	Genentech Inc	composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
SG186783A1 (en)	2010-06-24	2013-02-28	Genentech Inc	Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
EP2603232B1 (en)	2010-08-11	2019-09-25	Ironwood Pharmaceuticals, Inc.	Stable formulations of linaclotide
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
WO2012041328A1 (en)	2010-10-01	2012-04-05	Nsgene A/S	Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2012045274A1 (en)	2010-10-08	2012-04-12	Shanghai Kexin Biotech Co., Ltd.	Moesin modulators and uses thereof
CA2814030C (en)	2010-10-08	2019-04-30	Shanghai Kexin Biotech Co., Ltd.	Diagnostic and therapeutic uses of moesin fragments
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
US10487114B2 (en)	2011-04-27	2019-11-26	Beth Israel Deaconess Medical Center, Inc.	Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012167271A1 (en) *	2011-06-02	2012-12-06	Baxter International Inc.	Formulations of recombinant furin
MX347354B (es)	2011-08-17	2017-04-24	Ironwood Pharmaceuticals Inc	Tratamientos para trastornos gastrointestinales.
ES2936387T3 (es)	2011-10-31	2023-03-16	Hoffmann La Roche	Formulaciones de anticuerpos anti-il13
WO2013096516A1 (en)	2011-12-19	2013-06-27	Xoma Technology Ltd.	Methods for treating acne
JP2015509091A (ja)	2012-01-09	2015-03-26	ザスクリプスリサーチインスティテュート	ヒト化抗体
CA2863224A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
EP2968548B1 (en)	2013-03-15	2020-09-09	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for the generation and use of conformation-specific antibodies
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CA2918370A1 (en)	2013-07-18	2015-01-22	Fabrus, Inc.	Humanized antibodies with ultralong complementarity determining regions
JP6822839B2 (ja)	2013-09-13	2021-01-27	ザ・スクリップス・リサーチ・インスティテュート	修飾された治療剤、及びその組成物
CN105814083A (zh)	2013-10-15	2016-07-27	加州生物医学研究所	嵌合抗原受体t细胞开关和其用途
CN105829349B (zh)	2013-10-15	2023-02-03	斯克利普斯研究所	肽嵌合抗原受体t细胞开关和其用途
CN104623639A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
KR102455171B1 (ko)	2013-12-18	2022-10-14	더 스크립스 리서치 인스티튜트	변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
NL2014230B1 (en)	2015-02-04	2016-10-12	Stichting Vu-Vumc	Wound healing formulation.
MA41629A (fr)	2015-03-04	2018-01-09	Center For Human Reproduction	Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10800828B2 (en)	2015-03-26	2020-10-13	The Scripps Research Institute	Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en)	2015-04-15	2021-08-17	The Scripps Research Institute	Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016205488A1 (en)	2015-06-17	2016-12-22	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
US11510966B2 (en)	2016-04-15	2022-11-29	Evive Biotechnology (Shanghai) Ltd	Use of IL-22 in treating necrotizing enterocolitis
EP3529268B1 (en)	2016-10-19	2025-02-26	The Scripps Research Institute	Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3807644A4 (en)	2018-06-12	2022-07-06	Angiex, Inc.	ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
TWI856084B (zh)	2019-04-01	2024-09-21	美商建南德克公司	用於穩定含有蛋白質之配方之組合物及方法
CA3149494A1 (en)	2019-08-12	2021-02-18	Purinomia Biotech, Inc.	Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN115551594A (zh)	2019-10-24	2022-12-30	米诺陶治疗公司	经细胞因子修饰的嵌合抗体及其使用方法
MX2022006861A (es)	2019-12-04	2022-07-11	Scripps Research Inst	Agonistas del receptor glp2 y metodos de uso.
EP4106794A4 (en)	2020-02-19	2024-03-20	Evive Biotechnology (Shanghai) Ltd	METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
US20250197525A1 (en)	2021-04-28	2025-06-19	Minotaur Therapeutics, Inc.	Humanized chimeric bovine antibodies and methods of use
CA3217602A1 (en)	2021-05-06	2022-11-10	Kenneth Petersen	Prevention and treatment of chemotherapy-induced neuropathic pain
KR20240032010A (ko)	2021-06-09	2024-03-08	더 스크립스 리서치 인스티튜트	장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
CA3239550A1 (en)	2021-12-10	2023-06-15	Kenneth Petersen	Treatment of nociceptive pain
IL316289A (en)	2022-04-29	2024-12-01	Purinomia Biotech Inc	Methods and compositions for treating diseases and disorders driven by eosinophils
AU2024356800A1 (en)	2023-10-05	2026-04-02	Ashibio, Inc.	Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en)	2024-10-03	2026-04-09	Ashibio, Inc.	Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816568A (en) *	1986-05-16	1989-03-28	International Minerals & Chemical Corp.	Stabilization of growth hormones
AU1757092A (en) *	1991-03-28	1992-11-02	Genentech Inc.	Stable growth hormone metal ion formulations

1996
- 1996-06-25 ZA ZA965368A patent/ZA965368B/xx unknown
- 1996-06-28 CA CA002226523A patent/CA2226523A1/en not_active Abandoned
- 1996-06-28 CN CN96195537A patent/CN1190897A/zh active Pending
- 1996-06-28 PL PL96324379A patent/PL324379A1/xx unknown
- 1996-06-28 EP EP96922775A patent/EP0839049A1/en not_active Withdrawn
- 1996-06-28 BR BR9609741A patent/BR9609741A/pt not_active Application Discontinuation
- 1996-06-28 HU HU9802287A patent/HUP9802287A3/hu unknown
- 1996-06-28 KR KR1019980700283A patent/KR19990028981A/ko not_active Ceased
- 1996-06-28 JP JP9506179A patent/JPH11509212A/ja active Pending
- 1996-06-28 WO PCT/DK1996/000293 patent/WO1997003692A1/en not_active Ceased
- 1996-06-28 AU AU63534/96A patent/AU715997B2/en not_active Ceased
- 1996-06-28 IL IL12258396A patent/IL122583A0/xx unknown
- 1996-06-28 CZ CZ9894A patent/CZ9498A3/cs unknown
1998
- 1998-01-13 NO NO980155A patent/NO980155L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ9498A3 (cs)	1998-06-17
NO980155D0 (no)	1998-01-13
CN1190897A (zh)	1998-08-19
EP0839049A1 (en)	1998-05-06
NO980155L (no)	1998-01-13
HUP9802287A2 (hu)	1999-02-01
ZA965368B (en)	1997-01-14
HUP9802287A3 (en)	2000-10-30
KR19990028981A (ko)	1999-04-15
PL324379A1 (en)	1998-05-25
AU6353496A (en)	1997-02-18
MX9800358A (es)	1998-07-31
BR9609741A (pt)	1999-03-16
IL122583A0 (en)	1998-06-15
AU715997B2 (en)	2000-02-17
CA2226523A1 (en)	1997-02-06
WO1997003692A1 (en)	1997-02-06

Publication	Publication Date	Title
JPH11509212A (ja)	1999-08-17	亜鉛及び必要に応じてリシン又はカルシウムイオンでプレ処理された成長ホルモンを含む安定化医薬製剤
US5851992A (en)	1998-12-22	Treatment of growth hormone deficiency
RU2236250C2 (ru)	2004-09-20	Фармацевтическая композиция, содержащая гормон роста, аминокислоту и неионогенный детергент
US5705482A (en)	1998-01-06	Pharmaceutical formulation
US5654278A (en)	1997-08-05	Composition and method comprising growth hormone and leucine
JP4064454B2 (ja)	2008-03-19	成長ホルモンおよびイソロイシンを含んでなる医薬製剤
JP4064453B2 (ja)	2008-03-19	成長ホルモンおよびバリンを含んでなる医薬製剤
JP4064455B2 (ja)	2008-03-19	成長ホルモンおよびロイシンを含んでなる医薬製剤
US6022858A (en)	2000-02-08	Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5552385A (en)	1996-09-03	Pharmaceutical formulation
JPH10511964A (ja)	1998-11-17	成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
JPH11510483A (ja)	1999-09-14	成長ホルモン並びに少なくとも１個の塩基性アミノ酸残基及び少なくとも１個の酸性アミノ酸残基を含むペプチドを含む、安定化された医薬製剤
JPH10511963A (ja)	1998-11-17	成長ホルモン及びＬｙｓ−Ｘを含む安定化医薬製剤
MXPA98000358A (en)	1998-11-09	Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal
MXPA98000309A (en)	1998-11-09	Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac
KR19980701352A (ko)	1998-05-15	성장호르몬 및 Ｌｅｕ－Ｈｉｓ－Ｌｅｕ을 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND LEU-HIS-LEU)